Kissei Pharmaceutical's (TYO:4547) licensing partner, JW Pharmaceutical, launched TAVALISSE (fostamatinib) in South Korea for adult patients with chronic idiopathic thrombocytopenic purpura (ITP) who did not respond to prior treatments, according to a Tokyo bourse filing on Tuesday.
TAVALISSE, an oral spleen tyrosine kinase inhibitor, was originally developed by US-based Rigel Pharmaceuticals and reduces the destruction of platelets in ITP patients.
The drug has already been launched in the US, Europe, Canada, the Middle East, and Japan, and holds orphan drug status in several markets, including South Korea.
Kissei licensed South Korea rights to JW in 2021. The South Korean approval, granted in January 2025, followed Kissei's launch in Japan in April 2023.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。